Quoc Le-Nguyen
Chief Tech/Sci/R&D Officer en 89BIO, INC. .
Fortuna: 3 M $ al 31/03/2024
Perfil
Quoc Le-Nguyen is currently the Chief Technical Operations Officer & Head-Quality at 89bio, Inc. He previously worked as the Vice President-Manufacturing Operations at Bayer AG from 2007 to 2013 and as the SVP, Global Head-Technical Operations & Quality at Aduro BioTech, Inc. from 2015 to 2018.
Mr. Le-Nguyen completed his undergraduate degree at the University of California.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
89BIO INC
0.24% | 17/02/2024 | 222 149 ( 0.24% ) | 3 M $ | 31/03/2024 |
Cargos activos de Quoc Le-Nguyen
| Empresas | Cargo | Inicio |
|---|---|---|
| 89BIO, INC. | Chief Tech/Sci/R&D Officer | 01/03/2019 |
Antiguos cargos conocidos de Quoc Le-Nguyen.
| Empresas | Cargo | Fin |
|---|---|---|
| CHINOOK THERAPEUTICS, INC. | Corporate Officer/Principal | 01/07/2018 |
| BAYER AG | Corporate Officer/Principal | 01/09/2013 |
Formación de Quoc Le-Nguyen.
| University of California | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| BAYER AG | Health Technology |
| 89BIO, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Quoc Le-Nguyen
